Top FDA official seeks to hire friend pushing new antidepressants warning
-
By
-
Matthew Perrone
-
March 4, 2026
-
Clinical Scorecard: Senior FDA Official Aims to Recruit Colleague Advocating for New Antidepressant Safety Warnings
At a Glance
| Category | Detail |
|---|
| Condition | Depression treated with SSRIs during pregnancy |
| Key Mechanisms | Selective serotonin reuptake inhibitors (SSRIs) potentially linked to pregnancy complications and fetal brain development issues |
| Target Population | Pregnant women taking antidepressants |
| Care Setting | FDA regulatory review and clinical prescribing settings |
Key Highlights
- FDA official Dr. Tracy Beth Hoeg is advocating for new boxed warnings on SSRIs about unproven pregnancy risks.
- Critics argue the petition relies on limited data and warn that new warnings may lead to untreated maternal depression.
- Professional guidelines currently consider antidepressants generally safe during pregnancy with careful medical consultation.
Guideline-Based Recommendations
Diagnosis
- Depression diagnosis should consider risks and benefits of antidepressant use during pregnancy.
Management
- Antidepressants should be discontinued during pregnancy only after careful consultation with a healthcare provider.
Monitoring & Follow-up
- Pregnant women on SSRIs require monitoring for maternal mental health and fetal development.
Risks
- Current FDA labels include risks of suicidal behavior in children and some documented pregnancy safety issues.
- Proposed new warnings suggest possible miscarriage and fetal brain abnormalities, though evidence is contested.
Patient & Prescribing Data
More than 15% of U.S. women, approximately 26 million people, take medication for depression.
SSRIs are among the most commonly prescribed antidepressants; professional guidelines support their cautious use during pregnancy.
Clinical Best Practices
- Evaluate risks of untreated maternal depression alongside potential medication risks.
- Engage in shared decision-making with pregnant patients regarding antidepressant use.
- Avoid abrupt discontinuation of SSRIs without medical supervision.
- Consider current evidence and guideline recommendations before altering treatment based on new warnings.
References
